Exercise Effects in Huntington's Disease
Primary Purpose
Huntington's Disease
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Exercise training
Sponsored by
About this trial
This is an interventional treatment trial for Huntington's Disease
Eligibility Criteria
Inclusion criteria: Inclusion criteria for HD subjects are:
- Male gender
- Genetically verified diagnosis of HD
- Age 30 to 50 years
- Presence of only mild to moderate neurological, cognitive or muscular impairment allowing the subjects to give their written informed consent and to participate in the endurance training (UHDRS 30 or lower)
For healthy control participants, inclusion criteria are:
- male gender 9
- age 30 to 50 years
- absence of physical or mental illness
Exclusion criteria: Exclusion criteria for HD subjects are:
- Female gender
- Advanced neurological, cognitive or muscular impairment related to HD that does not allow patients to participate in the endurance training and/or to give their written informed consent
- Cardiovascular disease or any other medical condition that might not be compatible with endurance training
- CK levels > 300 U/L
Exclusion criteria for healthy control participants are:
- cardiovascular disease
- any other medical condition that might not be compatible with endurance training
- CK levels > 300 U/L.
Sites / Locations
- University Hospital Zurich, Division of Neurology
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Exercise Training: HD subjects
Exercise Training: healthy subjects
Arm Description
Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
6 months of exercise training (2 times 30 min per week)
Outcomes
Primary Outcome Measures
Change in Unified Huntington's Disease Rating Scale (UHDRS)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01879267
Brief Title
Exercise Effects in Huntington's Disease
Official Title
Exercise Effects in Huntington's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
January 2018 (Actual)
Study Completion Date
January 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Huntington's disease (HD) is an incurable and fatal disorder characterised by progressive degeneration of the basal ganglia and the cerebral cortex. Contrary to earlier thinking, HD is associated with abnormalities in peripheral tissues which might even contribute to brain pathology including muscle wasting, mitochondrial abnormalities, and impaired muscle energy metabolism. Mitochondrial impairment and muscle atrophy in human HD patients and murine models of HD are associated with altered expression of PGC-1a, a transcriptional cofactor that seems to regulate many, if not all of the adaptations of muscle fibres to chronic endurance training, and induces improved exercise performance and increased peak oxygen uptake. We aim at investigating whether endurance exercise has the capability of stabilizing and / or reversing PGC-1a dependent alterations of muscle function and structure in HD patients, and whether muscle training ameliorates musculoskeletal and cardiovascular function, as well as motor and cognitive symptoms in HD patients.
Detailed Description
Huntington disease (HD) is an incurable and fatal disorder that affects muscle function and leads to cognitive decline and dementia. HD was long considered a brain disorder but meanwhile it was shown that HD also affects other tissues such as muscle, leading to muscle wasting. Previous studies suggested that the muscle disorder might be caused by an impaired energy metabolism through mitochondrial dysfunction, which also might also contribute to brain pathology.
In muscle tissue of healthy persons, a protein named PGC 1- α seems to regulate many, if not all of the adaptations of muscle metabolism and mitochondrial biogenesis to chronic endurance training. It was shown that PGC 1- α is reduced in muscle tissue of human HD patients and animal models of HD.
We aim investigating whether endurance exercise has the capability of stabilizing and / or reversing PGC-1α dependent decline of muscle function and structure in HD patients, and whether muscle training ameliorates muscular and cardiovascular function, as well as coordination and cognitive decline in HD. To this end, we will train 20 male HD patients using a 6 months progressive endurance exercise program. In order to compare the size effect of exercise between HD patients and healthy individuals, 20 age-matched healthy males will perform the identical exercise regimen as HD patients. Within one week before the training period starts and within one week after it has ended, we will assess metabolic and functional data. In addition, we will analyze muscle tissue samples for muscle fiber structure, metabolic phenotype and cellular pathology. Finally, gene and protein expression analyses will be performed on muscle tissue extracts to gain insights into the molecular regulation of training adaptations in HD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Huntington's Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Exercise Training: HD subjects
Arm Type
Other
Arm Description
Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
Arm Title
Exercise Training: healthy subjects
Arm Type
Other
Arm Description
6 months of exercise training (2 times 30 min per week)
Intervention Type
Behavioral
Intervention Name(s)
Exercise training
Intervention Description
6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
Primary Outcome Measure Information:
Title
Change in Unified Huntington's Disease Rating Scale (UHDRS)
Time Frame
Baseline and 6 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Inclusion criteria for HD subjects are:
Male gender
Genetically verified diagnosis of HD
Age 30 to 50 years
Presence of only mild to moderate neurological, cognitive or muscular impairment allowing the subjects to give their written informed consent and to participate in the endurance training (UHDRS 30 or lower)
For healthy control participants, inclusion criteria are:
male gender 9
age 30 to 50 years
absence of physical or mental illness
Exclusion criteria: Exclusion criteria for HD subjects are:
Female gender
Advanced neurological, cognitive or muscular impairment related to HD that does not allow patients to participate in the endurance training and/or to give their written informed consent
Cardiovascular disease or any other medical condition that might not be compatible with endurance training
CK levels > 300 U/L
Exclusion criteria for healthy control participants are:
cardiovascular disease
any other medical condition that might not be compatible with endurance training
CK levels > 300 U/L.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans H Jung, Professor MD
Organizational Affiliation
University Hospital Zurich, Division of Neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Zurich, Division of Neurology
City
Zurich
State/Province
ZH
ZIP/Postal Code
8091
Country
Switzerland
12. IPD Sharing Statement
Citations:
PubMed Identifier
29258585
Citation
Mueller SM, Gehrig SM, Petersen JA, Frese S, Mihaylova V, Ligon-Auer M, Khmara N, Nuoffer JM, Schaller A, Lundby C, Toigo M, Jung HH. Effects of endurance training on skeletal muscle mitochondrial function in Huntington disease patients. Orphanet J Rare Dis. 2017 Dec 19;12(1):184. doi: 10.1186/s13023-017-0740-z.
Results Reference
derived
Learn more about this trial
Exercise Effects in Huntington's Disease
We'll reach out to this number within 24 hrs